{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:30:01Z","timestamp":1767907801374,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,30]]},"DOI":"10.7759\/cureus.14193","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T22:09:05Z","timestamp":1617142145000},"source":"Crossref","is-referenced-by-count":5,"title":["Advances in the Treatment of Polycythemia Vera: Trends in Disease Management"],"prefix":"10.7759","author":[{"given":"Yajur","family":"Arya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshi","family":"Syal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Gaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016, 127:2391-405. 10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24221","article-title":"Myeloproliferative neoplasms: a decade of discoveries and treatment advances","volume":"91","author":"Tefferi A","year":"2016","unstructured":"Tefferi A. Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol. 2016, 91:50-8. 10.1002\/ajh.24221","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.05.020","article-title":"Patient-reported outcomes data from reveal at the time of enrollment (baseline): a prospective observational study of patients with polycythemia vera in the United States","volume":"18","author":"Mesa R","year":"2018","unstructured":"Mesa R, Boccia RV, Grunwald MR, et al.. Patient-reported outcomes data from reveal at the time of enrollment (baseline): a prospective observational study of patients with polycythemia vera in the United States. Clin Lymphoma Myeloma Leuk. 2018, 18:590-596. 10.1016\/j.clml.2018.05.020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.480","article-title":"What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?","volume":"2017","author":"Vannucchi AM","year":"2017","unstructured":"Vannucchi AM, Guglielmelli P. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?. Hematology Am Soc Hematol Educ Program. 2017, 2017:480-488. 10.1182\/asheducation-2017.1.480","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-551929","article-title":"How I treat polycythemia vera","volume":"124","author":"Vannucchi AM","year":"2014","unstructured":"Vannucchi AM. How I treat polycythemia vera. Blood. 2014, 124:3212-20. 10.1182\/blood-2014-07-551929","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15648","article-title":"A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline","volume":"184","author":"McMullin MF","year":"2019","unstructured":"McMullin MF, Harrison CN, Ali S, et al.. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. Br J Haematol. 2019, 184:176-191. 10.1111\/bjh.15648","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi R","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004, 350:114-24. 10.1056\/NEJMoa035572","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.165126","article-title":"No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on low-dose aspirin in polycythemia vera and cytoreductive therapy in polycythemia vera clinical trials","volume":"102","author":"Barbui T","year":"2017","unstructured":"Barbui T, Carobbio A, Ghirardi A, Masciulli A, Rambaldi A, Vannucchi AM. No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on low-dose aspirin in polycythemia vera and cytoreductive therapy in polycythemia vera clinical trials. Haematologica. 2017, 102:e219-e221. 10.3324\/haematol.2017.165126","journal-title":"Haematologica"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.152769","article-title":"Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea","volume":"102","author":"Alvarez-Larr\u00e1n A","year":"2017","unstructured":"Alvarez-Larr\u00e1n A, P\u00e9rez-Encinas M, Ferrer-Mar\u00edn F, et al.. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica. 2017, 102:103-109. 10.3324\/haematol.2016.152769","journal-title":"Haematologica"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-0991-z","article-title":"Hydroxyurea and hydroxamic acid derivatives as antitumor drugs","volume":"64","author":"Saban N","year":"2009","unstructured":"Saban N, Bujak M. Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. Cancer Chemother Pharmacol. 2009, 64:213-21. 10.1007\/s00280-009-0991-z","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.221234","article-title":"Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis","volume":"104","author":"Ferrari A","year":"2019","unstructured":"Ferrari A, Carobbio A, Masciulli A, et al.. Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Haematologica. 2019, 104:2391-2399. 10.3324\/haematol.2019.221234","journal-title":"Haematologica"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23160","article-title":"Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN","volume":"87","author":"Antonioli E","year":"2012","unstructured":"Antonioli E, Guglielmelli P, Pieri L, et al.. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol. 2012, 87:552-4. 10.1002\/ajh.23160","journal-title":"Am J Hematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larr\u00e1n A","year":"2012","unstructured":"Alvarez-Larr\u00e1n A, Pereira A, Cervantes F, et al.. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012, 119:1363-9. 10.1182\/blood-2011-10-387787","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28441","article-title":"A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"Verstovsek S","year":"2014","unstructured":"Verstovsek S, Passamonti F, Rambaldi A, et al.. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014, 120:513-20. 10.1002\/cncr.28441","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi AM","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, et al.. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015, 372:426-35. 10.1056\/NEJMoa1409002","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2994-x","article-title":"Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study","volume":"96","author":"Vannucchi AM","year":"2017","unstructured":"Vannucchi AM, Verstovsek S, Guglielmelli P, et al.. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol. 2017, 96:1113-1120. 10.1007\/s00277-017-2994-x","journal-title":"Ann Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3365-y","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial","volume":"97","author":"Griesshammer M","year":"2018","unstructured":"Griesshammer M, Saydam G, Palandri F, et al.. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol. 2018, 97:1591-1600. 10.1007\/s00277-018-3365-y","journal-title":"Ann Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719870052","article-title":"Updates in the management of polycythemia vera and essential thrombocythemia","volume":"10","author":"Bose P","year":"2019","unstructured":"Bose P, Verstovsek S. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol. 2019, 10:2040620719870052. 10.1177\/2040620719870052","journal-title":"Ther Adv Hematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S177692","article-title":"Ruxolitinib in the treatment of polycythemia vera: an update on health-related quality of life and patient-reported outcomes","volume":"10","author":"Cingam S","year":"2019","unstructured":"Cingam S, Flatow-Trujillo L, Andritsos LA, Arana Yi C. Ruxolitinib in the treatment of polycythemia vera: an update on health-related quality of life and patient-reported outcomes. J Blood Med. 2019, 10:381-390. 10.2147\/JBM.S177692","journal-title":"J Blood Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.05.002","article-title":"A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia","volume":"60","author":"Verstovsek S","year":"2017","unstructured":"Verstovsek S, Courby S, Griesshammer M, et al.. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Leuk Res. 2017, 60:11-17. 10.1016\/j.leukres.2017.05.002","journal-title":"Leuk Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404180","article-title":"Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage","volume":"20","author":"Hong Y","year":"2006","unstructured":"Hong Y, Wang G, Arroyo AGD, Hernandez J, Skene C, Erusalimsky JD. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Leukemia. 2006, 20:1117-22. 10.1038\/sj.leu.2404180","journal-title":"Leukemia"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0335-0","article-title":"The use of anagrelide in myeloproliferative neoplasms, with focus on essential thrombocythemia","volume":"11","author":"Birgeg\u00e5rd G","year":"2016","unstructured":"Birgeg\u00e5rd G. The use of anagrelide in myeloproliferative neoplasms, with focus on essential thrombocythemia. Curr Hematol Malig Rep. 2016, 11:348-55. 10.1007\/s11899-016-0335-0","journal-title":"Curr Hematol Malig Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell PJ","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G, et al.. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005, 366:1945-53. 10.1016\/S0140-6736(05)67785-9","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui T","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, et al.. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018, 32:1057-1069. 10.1038\/s41375-018-0077-1","journal-title":"Leukemia"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.06.019","article-title":"Interferon \u03b1-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation","volume":"38","author":"Huang BT","year":"2014","unstructured":"Huang BT, Zeng QC, Zhao WH, Li BS, Chen RL. Interferon \u03b1-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Leuk Res. 2014, 38:1177-83. 10.1016\/j.leukres.2014.06.019","journal-title":"Leuk Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian JJ","year":"2008","unstructured":"Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008, 22:1990-8. 10.1038\/leu.2008.280","journal-title":"Leukemia"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1179\/102453309X12473408860587","article-title":"Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission","volume":"14","author":"Larsen TS","year":"2009","unstructured":"Larsen TS, M\u00f8ller MB, de Stricker K, et al.. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology. 2009, 14:331-4. 10.1179\/102453309X12473408860587","journal-title":"Hematology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.06.012","article-title":"Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha","volume":"37","author":"Larsen TS","year":"2013","unstructured":"Larsen TS, Iversen KF, Hansen E, et al.. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res. 2013, 37:1041-5. 10.1016\/j.leukres.2013.06.012","journal-title":"Leuk Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071954","article-title":"Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature","volume":"12","author":"How J","year":"2020","unstructured":"How J, Hobbs G. Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature. Cancers (Basel). 2020, 12:1954. 10.3390\/cancers12071954","journal-title":"Cancers (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"S\u00f8rensen AL","year":"2020","unstructured":"S\u00f8rensen AL, Mikkelsen SU, Knudsen TA, et al.. Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematologica. 2020, 105:2262-2272. 10.3324\/haematol.2019.235648","journal-title":"Haematologica"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0133-0","article-title":"Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo","volume":"8","author":"Verger E","year":"2018","unstructured":"Verger E, Soret-Dulphy J, Maslah N, et al.. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018, 8:94. 10.1038\/s41408-018-0133-0","journal-title":"Blood Cancer J"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165805","article-title":"New perspectives on polycythemia vera: from diagnosis to therapy","volume":"21","author":"Iurlo A","year":"2020","unstructured":"Iurlo A, Cattaneo D, Bucelli C, Baldini L. New perspectives on polycythemia vera: from diagnosis to therapy. Int J Mol Sci. 2020, 21:5805. 10.3390\/ijms21165805","journal-title":"Int J Mol Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger H","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, et al.. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020, 7:e196-e208. 10.1016\/S2352-3026(19)30236-4","journal-title":"Lancet Haematol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2016.1250882","article-title":"Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms","volume":"25","author":"Bose P","year":"2016","unstructured":"Bose P, Verstovsek S. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin Investig Drugs. 2016, 25:1393-1403. 10.1080\/13543784.2016.1250882","journal-title":"Expert Opin Investig Drugs"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.087742","article-title":"JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug","volume":"98","author":"Kuriakose ET","year":"2013","unstructured":"Kuriakose ET, Gjoni S, Wang YL, Baumann R, Jones AV, Cross NC, Silver RT. JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. Haematologica. 2013, 98:e135-7. 10.3324\/haematol.2013.087742","journal-title":"Haematologica"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2152-7","article-title":"Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea","volume":"93","author":"Alvarez-Larr\u00e1n A","year":"2014","unstructured":"Alvarez-Larr\u00e1n A, Mart\u00ednez-Avil\u00e9s L, Hern\u00e1ndez-Boluda JC, et al.. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol. 2014, 93:2037-43. 10.1007\/s00277-014-2152-7","journal-title":"Ann Hematol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405049","article-title":"The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)","volume":"22","author":"Guerini V","year":"2008","unstructured":"Guerini V, Barbui V, Spinelli O, et al.. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia. 2008, 22:740-7. 10.1038\/sj.leu.2405049","journal-title":"Leukemia"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi A","year":"2010","unstructured":"Rambaldi A, Dellacasa CM, Finazzi G, et al.. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010, 150:446-55. 10.1111\/j.1365-2141.2010.08266.x","journal-title":"Br J Haematol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12332","article-title":"A phase II study of givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy","volume":"161","author":"Finazzi G","year":"2013","unstructured":"Finazzi G, Vannucchi AM, Martinelli V, et al.. A phase II study of givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol. 2013, 161:688-94. 10.1111\/bjh.12332","journal-title":"Br J Haematol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0735-y","article-title":"Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib\/II study","volume":"34","author":"Rambaldi A","year":"2020","unstructured":"Rambaldi A, Lurlo A, Vannucchi AM, et al.. Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib\/II study. Leukemia. 2020, 34:2234-7. 10.1038\/s41375-020-0735-y","journal-title":"Leukemia"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/903435","article-title":"Roles of p53 in various biological aspects of hematopoietic stem cells","volume":"2012","author":"Nii T","year":"2012","unstructured":"Nii T, Marumoto T, Tani K. Roles of p53 in various biological aspects of hematopoietic stem cells. J Biomed Biotechnol. 2012, 2012:903435. 10.1155\/2012\/903435","journal-title":"J Biomed Biotechnol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536854","article-title":"The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon \u03b1 2a target JAK2V617F-positive progenitor and stem cells","volume":"124","author":"Lu M","year":"2014","unstructured":"Lu M, Xia L, Li Y, Wang X, Hoffman R. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon \u03b1 2a target JAK2V617F-positive progenitor and stem cells. Blood. 2014, 124:771-9. 10.1182\/blood-2013-11-536854","journal-title":"Blood"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410712","article-title":"Combination treatment in vitro with nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-\u03b1 2a specifically targets JAK2V617F-positive polycythemia vera cells","volume":"120","author":"Lu M","year":"2012","unstructured":"Lu M, Wang X, Li Y, et al.. Combination treatment in vitro with nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-\u03b1 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012, 120:3098-105. 10.1182\/blood-2012-02-410712","journal-title":"Blood"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018893545","article-title":"Oral idasanutlin in patients with polycythemia vera","volume":"134","author":"Mascarenhas J","year":"2019","unstructured":"Mascarenhas J, Lu M, Kosiorek H, et al.. Oral idasanutlin in patients with polycythemia vera. Blood. 2019, 134:525-533. 10.1182\/blood.2018893545","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/54981-advances-in-the-treatment-of-polycythemia-vera-trends-in-disease-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:48Z","timestamp":1707507108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/54981-advances-in-the-treatment-of-polycythemia-vera-trends-in-disease-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.14193","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,30]]}}}